Clinical Trial Update: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

This Phase 1 study of AMG 427 in relapsed/refractory acute myeloid leukemia assessed safety, tolerability, PK/PD, and preliminary efficacy; the study was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AMG 427

Snippet

Sponsor: Amgen | Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Status: TERMINATED | Results posted: 2024-10-10